Peptide-siRNA Conjugate
Recall Paul mentioned using their targeted delivery technology for siRNA.
“One of the most important advances in biology has been the discovery that siRNA small interfering RNA is able to regulate the expression of genes, by a phenomenon known as RNAi.”
It seems like that is a huge opportunity by itself.
For instance in cancer they target genes encoding the key proteins responsible for growth of cancer cells and vascular endothelial growth factor so the cancer either stabilized after six months, or regression of metastasis in some of the patients. The challenge for siRNA is intracellular delivery so that’s where endocytosis-mediated cell entry make a huge difference as for getting siRNA to targeted cells.
“Peptide-siRNA conjugate
The peptide-siRNA conjugate of BOC RNA is considered a potent drug delivery strategy since the short cell-penetrating peptide (CPP) is capable of carrying cargo into the cells owing to its easy penetration through the cell membranes. BOC RNA, working with its parent company BOC Sciences, builds a siRNA drug delivery platform that offers the design and synthesis of siRNA, high-quality peptides, as well as peptide-siRNA conjugates. Equipped with advanced technology, BOC RNA has been providing professional technical support for peptide-siRNA conjugation in the last few years.”
Read more: https://www.digitaljournal.com/pr/sirna-drug-delivery-platform-of-boc-rna-speeds-up-disease-treatment-research#ixzz7EyVGu7As
https://rna.bocsci.com/products-services/peptide-sirna-conjugates.html